Severin Schwan, Roche CEO (AP Images)

Roche to read out even more da­ta on megablock­buster Ocre­vus in MS

It’s been three years since Roche hit the mar­ket with its megablock­buster MS drug Ocre­vus — but the Swiss phar­ma isn’t done build­ing on the pro­gram that CEO Sev­erin Schwan has called the most suc­cess­ful launch in the com­pa­ny’s 124-year his­to­ry.

Roche says it’s go­ing to MSVir­tu­al2020 next week­end with new ef­fi­ca­cy da­ta for the treat­ment of mul­ti­ple scle­ro­sis (MS) and neu­romyelitis op­ti­ca spec­trum dis­or­der (NMOSD) pa­tients. Plus, it’s ini­ti­at­ing a Phase II­Ib study to eval­u­ate Ocre­vus at a high­er dose for re­laps­ing and pri­ma­ry pro­gres­sive MS pa­tients, and a Phase IV CHIMES study which will fo­cus on the drug’s ef­fi­ca­cy in African Amer­i­can, His­pan­ic and Lat­inx Amer­i­can pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA